期刊文献+

自体CIK细胞联合IL-2治疗难治性脾非霍奇金淋巴瘤1例 被引量:8

Treatment of refractory non-Hodgkin's lymphoma of the spleen with combined autologous cytokine induced killer cells and IL-2: A case report
原文传递
导出
摘要 目的观察自体细胞因子诱导的杀伤细胞输注联合IL-2治疗老年淋巴瘤的有效性和安全性。方法 1例老年脾脏恶性淋巴瘤患者在经过手术切除脾脏原发肿瘤、8个疗程的R-CHOP方案免疫化疗后出现淋巴瘤肝脏转移,此时采集患者外周血单核细胞,在体外经干扰素-γ(IFN-γ)、白介素-2(IL-2)和抗CD3单克隆抗体诱导成CIK细胞,每次回输细胞数为2-3×109个,回输后应用IL-2 100mU/d,皮下注射,连续10d,28d为1个周期。观察治疗前后患者肝功能、肿瘤相关生物学指标及影像学变化。结果患者共完成8个周期的CIK细胞输注,每次回输后未出现不良反应,肝功能指标、LDH水平均降至正常,PET/CT检查示治疗后肝脏淋巴瘤转移灶消失,达到完全缓解。结论自体CIK细胞输注联合IL-2疗法对于清除治疗后淋巴瘤的微小残留灶和(或)转移灶安全有效。 Objective To observe the efficiency and safety of combined autologous cytokine induced killer(CIK) cells and IL-2 in treatment of splenic lymphoma in old patients.Methods Hepatic metastasis of splenic primary malignant lymphoma occurred in an old patient after splenectomy and 8 cycles of R-CHOP chemotherapy.Peripheral blood mononuclear cells(PBMC) were collected.CIK cells were induced with in vitro interferon gamma(IFN-γ),IL-2 and anti-CD3 monoclonal antibody(mAb).Liver function,tumor-related biological indexes and image changes were observed after 2-3×109 CIK cells were re-transfused into the patient each time and IL-2 100mU/d was subcutaneously injected for 10 days,28 days a cycle.Results No adverse reaction occurred in the patient after 8 cycles of CIK cells transfusion.The liver function and serum LDH level became normal(P0.05).PET-CT showed that hepatic metastasis of lymphoma disappeared and completely relieved.Conclusion Combined autologous CIK cells and IL-2 is safe and effective for small residual or metastatic foci of lymphoma in old patients after splenectomy.
出处 《军医进修学院学报》 CAS 2012年第3期285-287,共3页 Academic Journal of Pla Postgraduate Medical School
基金 国家自然科学基金项目(30772597) 解放军总医院科技创新苗圃基金(11KMM24) 中央保健研究基金(B2009B115) 科技部新药创制重大专项(2008ZXJ09001-019)~~
关键词 细胞因子诱导的杀伤细胞 脾脏淋巴瘤 老年人 cytokine induced killer cells primary malignant lymphoma of the spleen aged
  • 相关文献

参考文献9

二级参考文献54

共引文献45

同被引文献110

  • 1江浩,刘开彦,童春容,江滨,陆道培.化疗联合自体细胞因子诱导杀伤细胞治疗急性白血病的临床观察[J].中华内科杂志,2005,44(3):198-201. 被引量:32
  • 2郭智,谭晓华,高锦,楼金星,刘晓东,何学鹏.CIK治疗耐药性非霍奇金淋巴瘤疗效观察[J].实用癌症杂志,2006,21(1):15-16. 被引量:29
  • 3Cheson BD, Bennett JM, Grever M, et al, National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 1996 ; 87 ( 12 ) : 4990 - 4997.
  • 4Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2004:163 - 183.
  • 5Ferlay J, Bray F, Pisani P, et al. GLOBOCAN2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base No. 5 Version 2. 0. France: L yon, IARC Press, 2004.
  • 6Homer M J, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975 - 2006, National Cancer Institute. Bethesda, MD, http: // seer. cancer, gov/csr/1975_ 2006 /, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
  • 7Rozman'(-, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med, 1995; 333 (16) : 1052 -1057.
  • 8Moddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol, 2009, 2:29.
  • 9Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells : first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 2011, 137(2) : 305 -310.
  • 10Harris NL, Jaffe ES, Diebold J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 1999; 17(12) : 3835-3849.

引证文献8

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部